Phytanix Bio Publishes New Investor Deck Highlighting Strategic Vision and Growth Potential

NEW YORK and SANTA BARBARA, Calif., July 30, 2024 – Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoidlike molecules, today announced the release of its new investor deck. The updated presentation provides an indepth look at the company's strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. Strategic Vision and Missio ...